Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease

NCT07488377 | Recruiting

• 1 other identifier: 2026-05-223
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)

  Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.

  Baseline and 14-21 days for test-retest assessment

Secondary Outcomes (2)

• Self-Efficacy for Managing Chronic Disease (6-Item Scale)

  Baseline

• Montreal Cognitive Assessment (MoCA-TR)

  Baseline

Interventions

Cognitive Self-Efficacy Questionnaire (Turkish Version) OTHER

Participants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.

Eligibility Criteria

• Age: 40 Years - 85 Years
• Gender Eligibility Details: Both male and female participants will be included in the study. No gender-based restrictions will be applied.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.

You may qualify if:

• Clinical diagnosis of Parkinson's disease
• Hoehn and Yahr stage 1-3
• Age 40 to 85 years
• Mini-Mental State Examination (MMSE) score ≥24
• Able to communicate and complete study assessments
• Attending the Movement Disorders Outpatient Clinic, Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital
• Able and willing to provide written informed consent

You may not qualify if:

• Major depressive disorder or psychotic disorder
• Advanced dementia
• Severe visual impairment that may interfere with study assessments
• Severe hearing impairment that may interfere with study assessments
• Inability to cooperate with the physiotherapist
• Inability to complete the study assessments

Sponsors & Collaborators

• Acibadem University: lead

Study Sites (1)

Acibadem University

Istanbul, Turkey, +90, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Nuray ALACA

CONTACT

05324251290; nuray.alaca@acibadem.edu.tr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof. Nuray Alaca

Study Record Dates

• First Submitted: March 18, 2026
• First Posted: March 23, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: July 15, 2026

Record last verified: 2026-07

Locations

TU (1)